An appeals court has opened another chapter in the long-running CRISPR patent saga. | An appeals court has opened another ...

The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 ...

Base-editing technologies along with AAV engineering not only help reduce costs but can also accelerate preclinical ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing ...

we are excited to have these tools utilized by the community and also apply this framework to other properties and enzymes in the genome editing repertoire." CRISPR-Cas9 enzymes can be used to ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

However, there are concerns that cutting the wrong gene or cutting too many times could cause genetic damage or new cancers. Peer and his team developed a CRISPR-Cas9 'delivery system' that uses ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics ... are interrelated. Access to basic services is another ESG risk Crispr ...

While CRISPR ... gene editing has led to powerful advances across biology, medicine, and agriculture, challenges persist in optimizing the editing efficiency of enzymes, such as the widely used ...